Cellectis drops one of its 3 clinical-stage CAR-Ts

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies.

The transatlantic biotech had been evaluating the CAR-T in question, dubbed UCART123, in a phase 1 study in relapsed or refractory acute myeloid leukemia.